What are the guidelines for treating Attention Deficit Hyperactivity Disorder (ADHD) in adults in Australia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 3, 2025 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Australian Guidelines for ADHD Treatment in Adults

For adult ADHD treatment in Australia, a multimodal approach is recommended with pharmacological treatment (stimulants as first-line) combined with psychosocial interventions for optimal outcomes.

Pharmacological Treatment Options

First-Line Medications

  • Stimulants are the first-line pharmacological treatment for adults with ADHD due to their strong evidence of efficacy 1
    • Methylphenidate formulations (short-acting, intermediate-acting, and long-acting) 2
    • Amphetamines (mixed amphetamine salts and lisdexamfetamine) have robust evidence of efficacy but require monitoring for side effects such as hypertension 3, 4

Second-Line Medications

  • Non-stimulants are recommended when stimulants are ineffective, not tolerated, or contraindicated 2, 4:
    • Atomoxetine (Strattera) 2
    • Extended-release guanfacine (Intuniv) 2
    • Extended-release clonidine (Kapvay) 2

Medication Management Considerations

  • Careful titration of medication doses is essential to achieve maximum benefit with minimum adverse effects 2
  • Regular monitoring for side effects including cardiovascular effects (increased blood pressure and heart rate), psychiatric adverse reactions, and growth suppression 5
  • Abuse potential assessment is necessary before prescribing stimulants, with education about proper storage and disposal 5
  • Treatment persistence tends to be lower in adults who initiated treatment in adolescence (19%) compared to those who began treatment in childhood (64-69%) 4

Non-Pharmacological Interventions

  • Cognitive Behavioral Therapy (CBT) has proven effectiveness for adults with ADHD 6
  • Psychoeducation about ADHD is recommended to improve understanding and management of the condition 2
  • Recovery-focused care that considers the individual's values, feelings, goals, and strengths 2

Australian-Specific Guidelines

  • The Australian ADHD Professionals Association (AADPA) has developed comprehensive evidence-based clinical practice guidelines for ADHD that are available online at https://adhdguideline.aadpa.com.au/ 1
  • These guidelines provide 113 clinical recommendations for various age groups, including adults 1
  • The "Talking About ADHD" language guide from AADPA aims to encourage language that fosters understanding and reduces stigma 2

Treatment Approach Algorithm

  1. Confirm diagnosis using appropriate diagnostic criteria and assessment tools
  2. Discuss treatment options with the patient, including benefits and risks of pharmacological and non-pharmacological interventions 1
  3. Initiate pharmacological treatment if indicated:
    • Start with stimulants (methylphenidate or amphetamine derivatives) 2
    • If ineffective or not tolerated, switch to alternative stimulant or non-stimulant medication 4
  4. Implement non-pharmacological interventions concurrently with medication 2, 6
  5. Regular monitoring of treatment efficacy, side effects, and functional outcomes 5
  6. Adjust treatment based on response and side effects 2

Common Pitfalls and Caveats

  • Undertreatment is common - treatment rates remain lower than the estimated prevalence of ADHD across all subpopulations in Australia 4
  • Transition from pediatric to adult care requires careful planning and monitoring due to poor long-term treatment persistence in this period 4
  • Comorbid conditions (substance use disorders, personality disorders, depression) are common in adults with ADHD and may complicate treatment 6
  • Medication misuse concerns exist but appear to be relatively low when appropriate monitoring is in place 7
  • Stimulant medications carry warnings about abuse, misuse, and addiction potential that require assessment and ongoing monitoring 5

Increasing Consumer Participation

  • Integration of consumer experience into research, service development, and ADHD-related training/education is recommended 2
  • Collaborative frameworks that guide researchers, practitioners, and consumers to work together can lead to better outcomes 2

By following these evidence-based guidelines, clinicians can provide effective treatment for adults with ADHD in Australia, improving outcomes and quality of life for these patients.

References

2
Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Related Questions

What does the self-reported 'high' from stimulants in a patient with attention deficit hyperactivity disorder (ADHD) correlate with, in terms of neurochemistry?
What are the suggested alternatives for a patient with Attention Deficit Hyperactivity Disorder (ADHD) combined type who experiences tachycardia on both immediate and extended-release (XR) formulations of Adderall (amphetamine and dextroamphetamine)?
What are the next treatment options for a 16-year-old patient with Attention Deficit Hyperactivity Disorder (ADHD), autism, Major Depressive Disorder (MDD), and Generalized Anxiety Disorder (GAD) who is currently taking Vyvanse (lisdexamfetamine) 60mg, Adderall (amphetamine) 10mg as needed, Intuniv (guanfacine) 2mg at night, and Zoloft (sertraline) 50mg daily with poor response to treatment?
What alternative medication regimen can a patient with ADHD, depression, and anxiety try if they experience decreased appetite and inadequate symptom control with their current regimen of Adderall, Concerta, Vyvanse, and Intuniv?
What is a cheaper, low-abuse potential alternative to Vyvanse (lisdexamfetamine) for treating ADHD in a patient with a history of bipolar disorder and alcohol use?
Does Allegra (fexofenadine) help with a runny nose?
What are the next steps for a patient with sleep apnea and insomnia who has not improved with 1mg of Lunesta (eszopiclone)?
Can a patient experience referred pain to the abdomen from an L1-L3 compression fracture due to shared innervation of the lumbar and abdominal regions?
What is the maximum recommended dose of sodium valproate?
What is the best treatment for gram-negative bacteremia?
How often should patients with sleep apnea have a sleep study conducted?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question